Bortezomib-High Dose Melphalan Conditioning for the Treatment of MM Patients Undergoing ASCT

被引：0
作者：
Jimenez-Zepeda, Victor [1 ]
Duggan, Peter [1 ]
Neri, Paola [2 ]
Chaudhry, Ahsan [3 ]
Tay, Jason [4 ]
Luider, Joanne [5 ]
Bahlis, Nizar J. [2 ,6 ]
机构：
[1] Tom Baker Canc Clin, Dept Med Oncol & Hematol, Calgary, AB, Canada
[2] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[3] Tom Baker Canc Clin, Calgary, AB, Canada
[4] Univ Calgary Tom Baker Canc Ctr, Calgary, AB, Canada
[5] Alberta Hlth Services, Calgary, AB, Canada
[6] Univ Calgary, Calgary, AB, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2273.2273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2273
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Modified High Dose Versus High Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis
    Edwards, Camille V.
    Brauneis, Dina
    Quillen, Karen
    Sanchorawala, Vaishali
    BLOOD, 2020, 136
  • [32] Bortezomib, Dexamethasone, and High-Dose Melphalan as Conditioning for Stem Cell Transplantation in Young Japanese Multiple Myeloma Patients: A Pilot Study
    Naoki Takezako
    Naohiro Sekiguchi
    Akihisa Nagata
    Chiho Homma
    Satoshi Noto
    Akiyoshi Miwa
    Indian Journal of Hematology and Blood Transfusion, 2013, 29 : 147 - 151
  • [33] Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
    Lee, Se Ryeon
    Choi, Hojoon
    Lee, Byung Hyun
    Kang, Ka-Won
    Yu, Eun Sang
    Kim, Dae Sik
    Park, Yong
    Choi, Chul Won
    Kim, Byung Soo
    Sung, Hwa Jung
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (06) : 1333 - 1346
  • [34] Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
    P Gimsing
    Ø Hjertner
    N Abildgaard
    N F Andersen
    T G Dahl
    H Gregersen
    T W Klausen
    U-H Mellqvist
    O Linder
    R Lindås
    N Tøffner Clausen
    S Lenhoff
    Bone Marrow Transplantation, 2015, 50 : 1306 - 1311
  • [35] A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support
    Gimsing, Peter
    Hjertner, Oyvind
    Abildgaard, Niels
    Andersen, Niels Frost
    Dahl, Tobias Gedde
    Gregersen, Henrik
    Mellqvist, Ulf-Henrik
    Linder, Olle
    Lindas, Roald
    Clausen, Niels-Aage Tofner
    Lenhoff, Stig
    BLOOD, 2011, 118 (21) : 1325 - 1326
  • [36] BORTEZOMIB WITH HIGH DOSE MELPHALAN CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IS SAFE AND IMPROVES THE RESPONSE RATE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Dalla Palma, B.
    Prezioso, L.
    Accardi, F.
    Rossetti, E.
    Aversa, F.
    Giuliani, N.
    HAEMATOLOGICA, 2015, 100 : 160 - 160
  • [37] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
    Dunia, D. M.
    Dolores, M.
    Dolores, S.
    Nuria, G.
    Miguel, D.
    Jaime, A.
    Helga, G.
    Alejandro, V.
    Sonia, H.
    Blanca, P.
    HAEMATOLOGICA, 2016, 101 : 862 - 862
  • [38] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
    de Miguel, D.
    Morales, D.
    San Roman, I.
    Golbano, N.
    Diaz, M.
    Arbeteta, J.
    Herrero, S.
    Subira, D.
    PInedo, B.
    HAEMATOLOGICA, 2012, 97 : 622 - 622
  • [39] Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up
    Nishiyama, Risa
    Kagoo, Toshiya
    Ueno, Hironori
    Yokoyama, Akihiro
    IN VIVO, 2025, 39 (01): : 340 - 345
  • [40] Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma
    P A Thompson
    H M Prince
    J F Seymour
    D Ritchie
    K Stokes
    K Burbury
    M Wolf
    S Peinert
    T Joyce
    S J Harrison
    Bone Marrow Transplantation, 2011, 46 : 764 - 765
12345